Skip to content
Dezocine
Dalgan (dezocine) is a small molecule pharmaceutical. Dezocine was first approved as Dalgan on 1989-12-29. It is used to treat pain in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dezocine
Tradename
Company
Number
Date
Products
DALGANAstraZenecaN-019082 DISCN1989-12-29
3 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
N02: Analgesics
N02A: Opioid analgesics
N02AX: Other opioids in atc
N02AX03: Dezocine
HCPCS
No data
Clinical
Clinical Trials
164 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AnesthesiaD0007581361019
General anesthesiaD000768111147
ObesityD009765EFO_0001073E66.91315
DeliriumD003693R41.0325
Postoperative cognitive complicationsD00007969011225
Coronary artery bypassD001026EFO_0003776123
Colorectal neoplasmsD0151791113
ArthritisD001168EFO_0005856M05-M1422
Delayed emergence from anesthesiaD055191112
Prostatic neoplasmsD011471C6122
Show 38 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative painD010149G89.181124
HepatectomyD006498112
Musculoskeletal diseasesD00914011
CystoscopesD02068411
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Postoperative nausea and vomitingD020250EFO_0004888112
Replacement arthroplasty kneeD01964511
Orthopedic proceduresD01963711
Down syndromeD004314EFO_0001064Q9011
Kidney transplantationD01603011
Drug-related side effects and adverse reactionsD064420T88.711
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hip fracturesD006620EFO_0003964S72.0022
Anesthesia recovery periodD00076222
Inhalation anesthesiaD00076922
Pituitary neoplasmsD01091122
Dna damageD00424922
HypotensionD007022EFO_0005251I9511
RhytidoplastyD01536111
Sleep wake disordersD012893G4711
Animal mammary neoplasmsD01567411
Enhanced recovery after surgeryD00008048211
Show 40 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDEZOCINE
INNdezocine
Description
Dezocine is (7S,8S)-7-Amino-8-methyl-5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogen at position 8 and one of the hydrogens at position 6 are substituted by each end of a tetramethylene bridge. A synthetic opioid analgesic, it has mixed opiod agonist and antagonist properties. Although it is used for pain management, it can produce opioid withdrawal syndrome in patients already dependent on other opioids, and its clinical application is limited by side effects such as dizziness. It has a role as an opioid analgesic. It is a member of phenols and a primary amino compound.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N
Identifiers
PDB
CAS-ID53648-55-8
RxCUI22713
ChEMBL IDCHEMBL1685
ChEBI ID4474
PubChem CID3033053
DrugBankDB01209
UNII IDVHX8K5SV4X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 579 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,071 adverse events reported
View more details